Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support.

Journal Article (Journal Article;Review)

Standard therapies for advanced low-grade lymphomas are not likely to provide a cure, prompting the use of more aggressive approaches. Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have a prolonged disease-free survival, although the benefit to overall survival remains unproven. Patients with chemotherapy-sensitive intermediate- or high-grade relapsed disease have improved survival with high-dose therapy, and those with high-risk disease may benefit from early consolidation while in first remission. Significant questions remain in terms of the proper timing of high-dose therapy, appropriate stratification by risk factors, the value of purging, the role of radiotherapy after transplantation, and the most appropriate source of stem cells for transplantation.

Full Text

Duke Authors

Cited Authors

  • Rizzieri, DA; Chao, NJ

Published Date

  • September 1997

Published In

Volume / Issue

  • 9 / 5

Start / End Page

  • 420 - 427

PubMed ID

  • 9327219

International Standard Serial Number (ISSN)

  • 1040-8746

Digital Object Identifier (DOI)

  • 10.1097/00001622-199709050-00005


  • eng

Conference Location

  • United States